B-intervention	0	1	L
I-intervention	1	2	-
I-intervention	2	11	Thyroxine
O	12	18	intake
O	19	21	as
O	22	23	a
O	24	33	potential
O	34	38	risk
O	39	45	factor
O	46	49	for
O	50	53	the
O	54	65	development
O	66	68	of
O	69	76	fatigue
O	77	79	in
O	80	86	breast
O	87	93	cancer
O	94	102	patients
O	103	113	undergoing
O	114	126	chemotherapy
O	126	127	.

O	128	129	L
O	129	130	-
O	130	139	Thyroxine
O	140	142	is
O	143	146	one
O	147	149	of
O	150	153	the
O	154	158	most
O	159	167	commonly
O	168	178	prescribed
O	179	184	drugs
O	185	188	and
O	189	200	accordingly
O	201	205	used
O	206	208	by
O	209	213	many
O	214	220	breast
O	221	227	cancer
O	228	236	patients
O	237	241	with
O	242	249	thyroid
O	250	259	disorders
O	259	260	.

O	261	266	Hence
O	266	267	,
O	268	277	potential
O	278	290	interactions
O	291	293	of
O	294	306	chemotherapy
O	307	311	with
O	312	313	L
O	313	314	-
O	314	323	thyroxine
O	323	324	,
O	325	333	possibly
O	334	346	contributing
O	347	349	to
O	350	357	fatigue
O	357	358	,
O	359	364	would
O	365	367	be
O	368	370	of
O	371	375	high
O	376	384	clinical
O	385	394	relevance
O	394	395	.

O	396	405	Therefore
O	405	406	,
O	407	409	we
O	410	422	investigated
O	423	430	fatigue
O	431	434	and
O	435	445	underlying
O	446	454	pathways
O	455	457	in
O	458	459	L
O	459	460	-
O	460	469	thyroxine
O	469	470	-
O	470	475	using
O	476	482	breast
O	483	489	cancer
O	490	498	patients
O	499	505	during
O	506	518	chemotherapy
O	518	519	.

O	520	527	Thyroid
O	527	528	-
O	528	539	stimulating
O	540	547	hormone
O	548	549	(
O	549	552	TSH
O	552	553	)
O	553	554	,
O	555	556	L
O	556	557	-
O	557	573	triiodothyronine
O	574	575	(
O	575	577	T3
O	577	578	)
O	578	579	,
O	580	583	and
O	584	591	diurnal
O	592	600	salivary
O	601	609	cortisol
O	610	618	patterns
O	619	623	were
O	624	632	analyzed
O	633	635	in
O	636	642	breast
O	643	649	cancer
O	650	658	patients
O	659	661	in
O	662	665	the
O	666	675	beginning
O	676	679	and
O	680	682	at
O	683	686	the
O	687	690	end
O	691	693	of
O	694	702	adjuvant
O	703	715	chemotherapy
O	716	722	within
O	723	726	the
B-control	727	734	control
I-control	735	740	group
O	741	742	(
O	742	743	n
O	744	745	=
B-control-participants	746	748	41
O	748	749	)
O	750	752	of
O	753	754	a
O	755	765	randomized
O	766	774	exercise
O	775	787	intervention
O	788	793	trial
O	793	794	.

O	795	807	Additionally
O	807	808	,
O	809	822	relationships
O	823	825	in
O	826	829	the
O	830	840	exercising
O	841	846	group
O	847	848	(
O	848	849	n
O	850	851	=
B-intervention-participants	852	854	45
O	854	855	)
O	856	858	as
O	859	863	well
O	864	866	as
O	867	869	in
O	870	877	healthy
O	878	883	women
O	884	885	(
O	885	886	n
O	887	888	=
B-intervention-participants	889	891	25
O	891	892	)
O	893	897	were
O	898	906	explored
O	906	907	.

O	908	918	Regression
O	919	922	and
O	923	932	mediation
O	933	941	analyses
O	942	946	were
O	947	956	performed
O	956	957	.

O	958	959	L
O	959	960	-
O	960	969	Thyroxine
O	970	973	use
O	974	977	was
O	978	991	significantly
O	992	1002	associated
O	1003	1007	with
O	1008	1013	lower
B-outcome	1014	1017	TSH
O	1018	1019	(
O	1019	1025	median
O	1026	1027	=
B-iv-cont-median	1028	1029	0
I-iv-cont-median	1029	1030	.
I-iv-cont-median	1030	1032	33
I-iv-cont-median	1033	1035	mU
I-iv-cont-median	1035	1036	/
I-iv-cont-median	1036	1037	l
O	1037	1038	,
O	1039	1052	interquartile
O	1053	1058	range
O	1059	1060	=
O	1061	1062	(
O	1062	1063	0
O	1063	1064	.
O	1064	1066	15
O	1066	1067	-
O	1067	1068	0
O	1068	1069	.
O	1069	1071	48
O	1071	1072	)
O	1072	1073	)
O	1073	1074	,
O	1075	1082	whereas
O	1083	1091	patients
O	1092	1095	not
O	1096	1101	using
O	1102	1103	L
O	1103	1104	-
O	1104	1113	thyroxine
O	1114	1117	had
O	1118	1121	TSH
O	1122	1132	comparable
O	1133	1135	to
O	1136	1143	healthy
O	1144	1149	women
O	1150	1151	(
B-cv-cont-median	1151	1152	0
I-cv-cont-median	1152	1153	.
I-cv-cont-median	1153	1155	51
I-cv-cont-median	1156	1158	mU
I-cv-cont-median	1158	1159	/
I-cv-cont-median	1159	1160	l
O	1161	1162	(
O	1162	1163	0
O	1163	1164	.
O	1164	1166	37
O	1166	1167	-
O	1167	1168	0
O	1168	1169	.
O	1169	1171	74
O	1171	1172	)
O	1172	1173	)
O	1173	1174	.

B-outcome	1175	1177	T3
O	1178	1191	significantly
O	1192	1200	declined
O	1201	1207	during
O	1208	1220	chemotherapy
O	1221	1223	in
O	1224	1225	L
O	1225	1226	-
O	1226	1235	thyroxine
O	1236	1241	users
O	1242	1245	but
O	1246	1249	not
O	1250	1252	in
O	1253	1256	non
O	1256	1257	-
O	1257	1262	users
O	1262	1263	.

O	1264	1271	However
O	1271	1272	,
O	1273	1276	the
O	1277	1282	group
O	1283	1293	difference
O	1294	1300	failed
O	1301	1312	statistical
O	1313	1325	significance
O	1325	1326	.

O	1327	1328	L
O	1328	1329	-
O	1329	1338	Thyroxine
O	1339	1348	treatment
O	1349	1352	was
O	1353	1366	significantly
O	1367	1377	associated
O	1378	1382	with
O	1383	1392	increased
B-outcome	1393	1401	physical
I-outcome	1402	1409	fatigue
O	1410	1416	during
O	1417	1429	chemotherapy
O	1430	1431	(
O	1431	1432	p
O	1433	1434	=
O	1435	1436	0
O	1436	1437	.
O	1437	1440	004
O	1440	1441	)
O	1442	1444	in
O	1445	1448	the
O	1449	1452	non
O	1452	1453	-
O	1453	1463	exercising
O	1464	1469	group
O	1469	1470	.

O	1471	1475	This
O	1476	1487	association
O	1488	1496	appeared
O	1497	1499	to
O	1500	1502	be
O	1503	1509	partly
O	1510	1518	mediated
O	1519	1521	by
O	1522	1525	TSH
O	1525	1526	.

O	1527	1534	Further
O	1534	1535	,
O	1536	1539	TSH
O	1540	1548	appeared
O	1549	1551	to
O	1552	1558	affect
B-outcome	1559	1566	fatigue
O	1567	1573	partly
O	1574	1577	via
O	1578	1587	increased
O	1588	1596	cortisol
O	1597	1603	levels
O	1603	1604	.

O	1605	1607	In
O	1608	1611	the
O	1612	1620	exercise
O	1621	1626	group
O	1626	1627	,
O	1628	1633	there
O	1634	1637	was
O	1638	1640	no
O	1641	1652	significant
O	1653	1664	association
O	1665	1672	between
O	1673	1674	L
O	1674	1675	-
O	1675	1684	thyroxine
O	1685	1688	and
B-outcome	1689	1696	fatigue
O	1696	1697	.

O	1698	1699	L
O	1699	1700	-
O	1700	1709	Thyroxine
O	1710	1719	treatment
O	1720	1726	during
O	1727	1739	chemotherapy
O	1740	1745	might
O	1746	1752	result
O	1753	1755	in
B-outcome	1756	1764	hormonal
I-outcome	1765	1779	dysregulations
O	1780	1784	that
O	1785	1788	can
O	1789	1799	contribute
O	1800	1802	to
O	1803	1812	increased
O	1813	1821	physical
O	1822	1829	fatigue
O	1829	1830	.

O	1831	1840	Therefore
O	1840	1841	,
O	1842	1848	breast
O	1849	1855	cancer
O	1856	1864	patients
O	1865	1867	on
O	1868	1869	L
O	1869	1870	-
O	1870	1879	thyroxine
O	1880	1889	treatment
O	1890	1893	may
O	1894	1898	need
O	1899	1906	special
O	1907	1917	monitoring
O	1918	1920	of
O	1921	1926	their
O	1927	1934	thyroid
O	1935	1941	levels
O	1942	1945	and
O	1946	1948	of
O	1949	1956	fatigue
O	1957	1963	during
O	1964	1976	chemotherapy
O	1977	1980	and
O	1981	1987	should
O	1988	1990	be
O	1991	2001	encouraged
O	2002	2004	to
O	2005	2013	exercise
O	2013	2014	.

O	2015	2029	ClinicalTrials
O	2029	2030	.
O	2030	2033	gov
O	2034	2045	NCT01106820
O	2045	2046	.
